Glaxosmithkline | GSK - Ebitda


Glaxosmithkline reported GBP2.93B in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Aurora Cannabis CAD 799K 2.9M Jun/2026
Bausch Health Companies USD 1.31B 230M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Canopy Growth CAD 8M 145M Jun/2026
Corcept Therapeutics USD 115.75M 73.59M Sep/2026
Drreddys Laboratories INR 18.79B 10.16B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
J&J USD 8.99B 721M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Pacira USD 50.45M 1.78M Sep/2026
Perrigo USD 156.6M 83M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 89.44M 28.2M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Teva Pharmaceutical Industries USD 1.5B 1.02B Sep/2026
Zoetis USD 1.07B 21M Sep/2026